Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

<p>Figure S7 page2</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Craig M. Goodwin (14955973) (author)
Diğer Yazarlar:	Andrew M. Waters (14953065) (author), Jennifer E. Klomp (14961282) (author), Sehrish Javaid (14961285) (author), Kirsten L. Bryant (14955976) (author), Clint A. Stalnecker (14955952) (author), Kristina Drizyte-Miller (14961288) (author), Bjoern Papke (14961291) (author), Runying Yang (14961294) (author), Amber M. Amparo (14961297) (author), Irem Ozkan-Dagliyan (14961300) (author), Elisa Baldelli (14961303) (author), Valerie Calvert (14961306) (author), Mariaelena Pierobon (14961309) (author), Jessica A. Sorrentino (14961312) (author), Andrew P. Beelen (14961315) (author), Natalie Bublitz (14961318) (author), Mareen Lüthen (14961321) (author), Kris C. Wood (14961324) (author), Emanuel F. Petricoin (14961327) (author), Christine Sers (12163648) (author), Autumn J. McRee (14961330) (author), Adrienne D. Cox (14953077) (author), Channing J. Der (14961333) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Biology Molecular and Cellular Biology Cell Cycle CDKs and CDK inhibitors Cell Signaling Guanine nucleotide binding proteins and effectors DNA Damage and Repair DNA damage Oncogenes & Tumor Suppressors Kras Oncogenes Rb and family
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Yazar:: Juliana Navarro-Yepes (17079059)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
Yazar:: Katrina M. Lappin (9340394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
Yazar:: Sami Belhadj (15052341)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
Yazar:: Min Wei (16918572)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
Yazar:: Min Wei (16918572)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
Yazar:: Koichi Tomoshige (15304682)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Yazar:: Long Jiang (14956159)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
Yazar:: Lenka Stolarova (16547259)
Baskı/Yayın Bilgisi: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
Yazar:: Lenka Stolarova (16547259)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6qkkcql320gkvlem01tjh096bs